Ashkelon, Israel

Time filter

Source Type

Patent
Integrity Applications | Date: 2016-12-21

A hinge pin joint for facilitating precise separation of the jaws of a spring clip, including a base cylinder with a threaded bore, supports extending laterally out from the base cylinder, pin supports capable of pivoting, and stabilizing wings extending from the pin supports. In one embodiment, the capability of pivoting includes pins that are integral with the pin supports and which extend out laterally from the pin support. An alternate embodiment includes aligned opening in the pin supports into which pins may be inserted. At least one stopper may be disposed on at least one of the pin supports for supporting the upper shell. The stabilizing wings are configured as plates that are semi-rigidly secured in guide structures within the lower shell.


Mr. Hauck is currently the Executive Director of The Getz Group, a privately owned pan-Asian trading company focused on healthcare, industrial products, consumer distribution and retailing. He previously held executive and director level positions at various companies including, ERM, Interpharma Investments Ltd, Invida Holdings, Target Worldwide Express, 3i plc, Springboard, and Business Health Group Ltd. Mr. Hauck also served as the CEO of Walsh International for eight years, where he led the company's IPO and eventual sale to IMS Health. Mr. Hauck commented, "I am delighted to be a part of Integrity Applications, which is changing the way glucose is monitored and diabetes is managed. I am excited about the prospects for the company's innovative non-invasive glucose monitoring technology, GlucoTrack, to transform diabetes management, but especially the potential to expand its offering to provide valuable data and insights to healthcare professionals. I look forward to working with the Integrity Applications team as the company continues its expansion." About GlucoTrack® GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level in about a minute without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used for a projected HbA1c level using a proprietary algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only. About Integrity Applications, Inc. Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and prediabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrity-applications-glucotrack-innovator-expands-board-of-directors-with-the-appointment-of-michael-hauck-300463739.html


For more information, please visit the company website at www.integrity-app.com. About GlucoTrack® GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The derived glucose measurements are stored in the device and calculates a projected HbA1c level using a validated algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only. About Integrity Applications, Inc. Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and pre-diabetes. The company has developed GlucoTrack®, a proprietary noninvasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrity-applications-to-present-glucotrack-data-at-american-diabetes-associations-77th-scientific-sessions-300462076.html


— The “Continuous Glucose Monitoring Systems Market - Medical Devices Pipeline Assessment, 2017” the report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products. Browse the 157 Tables and Figures, 70 Companies, Spread across 268 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=958615. Scope of the Report: Extensive coverage of the Continuous Glucose Monitoring Systems under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Companies are mentioned: A. Menarini Diagnostics S.r.l., Abbott Diabetes Care, Inc., Advanced Biosensors-Ohio, Llc, Advanced Medical Electronics Corporation, Arkal Medical, Inc., Bio-Impedance General Ltd., Biorasis, Inc., Biovotion AG, CALISTO MEDICAL, INC. (Inactive), Cardiff University Company, City, University of London, Columbia University, ConvaTec Group Plc, Cyber Medical Ltd., Debiotech SA, DexCom Inc, DirectSens GmbH, Echo Therapeutics Inc, Ecole Polytechnique Federale de Lausanne, eLutions Integrated, EyeSense GmbH, Flowsion A/S, Gili Medical Ltd, Globe Medical Tech Inc, and Others. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=958615. Continuous Glucose Monitoring Systems Market- Recent Developments : Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand Mar 29, 2017: ConvaTec Group: Directorate changes Mar 28, 2017: Novo Acquires 19.95% Stake in Convatec from Nordic Capital and Avista for USD1.22 Billion Mar 28, 2017: ConvaTec: Proposed Directorate Changes Mar 27, 2017: Integrity Applications Board Appoints John Graham CEO and Chairman, Angela Strand Vice Chairman Mar 24, 2017: Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy Mar 21, 2017: Medtronic Prices Public Offering of 1.7% Notes Due 2019 for USD1 Billion Mar 21, 2017: Medtronic Prices Public Offering of 3.35% Notes Due 2027 for USD850 Million Mar 21, 2017: Medtronic Prices Public Offering of 4.625% Notes Due 2045 for USD150 Million Mar 21, 2017: Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update Mar 14, 2017: PositiveID’s E-N-G Mobile Systems’ 2017 Bookings Through February Total $1.7 Million, Up More than 200% from Prior Quarter Mar 13, 2017: DexCom Appoints Richard Collins to Board of Directors Mar 08, 2017: Tandem Diabetes Care Reports 2016 Financial Results Continuous Glucose Monitoring Systems Market- Recent Developments for 2017, January and February is also mentioned. List of Tables Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Segment Table 3: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Table 4: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Table 5: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date And more List of Figures Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Figure 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Figure 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date Figure 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials Complete Table of Content is Available at Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2017. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/958615-continuous-glucose-monitoring-systems-medical-devices-pipeline-assessment-2017.html


Patent
Integrity Applications | Date: 2014-03-05

A hinge pin joint for facilitating precise separation of the jaws of a spring clip, comprising: a base cylinder with a threaded bore; supports extending laterally out from said base cylinder; pin supports having means for pivoting; and stabilizing wings extending from the pin supports. In one embodiment, the means for pivoting includes pins that are integral with the pin supports and which extend out laterally from the pin support. An alternate embodiment comprises aligned openings in the pin supports into which pins may be inserted. At least one stopper may be disposed on at least one of the pin supports for supporting the upper shell. The stabilizing wings are configured as plates that are semi-rigidly secured in guide structures within the lower shell.


Patent
Integrity Applications | Date: 2014-08-20

In order to, increase the accuracy of non-invasive glucose measurement, the device uses a combination of three non-invasive methods: ultrasonic, electromagnetic and thermal. The non-invasive glucose monitor comprises a Main Unit, which drives three different sensor channels (one per technology), located on an external unit configured as an ear clip attached to the subjects ear lobe. To effect the ultrasonic channel, ultrasonic piezo elements are positioned on opposing portions of the ear clip and thus opposite sides of the ear lobe. For implementation of the electromagnetic channel, capacitor plates are positioned on opposing portions of the ear clip and the ear lobe serves as the dielectric. The thermal channel includes a heater and a sensor positioned on the ear clip in close juxtaposition to the ear lobe.


Patent
Integrity Applications | Date: 2012-07-03

In order to increase the accuracy of non-invasive glucose measurement, the device uses a combination of three non-invasive methods: ultrasonic, electromagnetic and thermal. The non-invasive glucose monitor comprises a Main Unit, which drives three different sensor channels (one per technology), located on an external unit configured as an ear clip attached to the subjects ear lobe. To effect the ultrasonic channel, ultrasonic piezo elements are positioned on opposing portions of the ear clip and thus opposite sides of the ear lobe. For implementation of the electromagnetic channel, capacitor plates are positioned on opposing portions of the ear clip and the ear lobe serves as the dielectric. The thermal channel includes a heater and a sensor positioned on the ear clip in close juxtaposition to the ear lobe.


News Article | February 16, 2017
Site: www.prnewswire.com

ASHDOD, Israel, Feb. 16, 2017 /PRNewswire/ -- Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a noninvasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that it is presenting this week at the 10th International...


GlucoTrack® is a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes that does not require pricking of the fingers to draw blood for daily glucose monitoring. GlucoTrack® features a small sensor that clips to the earlobe and measures the wearer's glucose level by taking measurements using three technologies. The measured signals are analyzed using a proprietary algorithm and displayed on a small handheld device the size of a mobile phone. The derived glucose measurement is also announced verbally, facilitating use by elderly and vision-impaired diabetes patients. The GlucoTrack® Model DF-F is expected to begin clinical trials for United States FDA approval in early 2017. The product is currently experimental in the United States and is limited to investigational use only. GlucoTrack® Model DF-F obtained a CE Mark approval in Europe (June 2013) and final CE Mark approval in March 2014 and in December 2015 received approval to market the device also to pre-diabetics. Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack® model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications operates primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information, please visit www.integrity-app.com and www.glucotrack.com. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC on March 30, 2016. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.


News Article | November 16, 2016
Site: www.newsmaker.com.au

WiseGuyReports.Com Publish a New Market Research Report On – “Self-Care Medical Devices 2016 Global Market Share,Growth,Trends & Forecast to 2020”. This market research study offers a comprehensive analysis of the global self-care medical devices market by application (SMBG, peritoneal dialysis, sleep apnea, insulin pumps, body temperature monitors, inhalers, pedometers, blood pressure monitors, nebulizers, male external catheters, and Holter monitors), and by geography (the Americas, APAC, and EMEA). Major vendors in this market are Abbott, Johnson & Johnson (J&J), Medtronic, Omron, Philips, and Roche Diagnostics. Overview of the global self-care medical devices market  The market research analyst predicts that the global self-care devices market will grow at a steady CAGR of approximately 9% during the forecast period. Factors such as public awareness have resulted in the need for self-care devices. Increased knowledge of one’s heath condition and the advantages of using devices like insulin pumps and glucose monitors have played a significant role in market demand. Moreover, device manufacturers are focused on offering easy to use and portable devices so that patients can take a more active role in monitoring their health. Additionally, awareness programs by various medical associations will help to increase the market growth of self-care medical devices during the forecast period. For more information or any query mail at [email protected] Advances in technology have played a significant role in product innovation and also ease of use. Current market trends show that wearable technology has made it easier for consumers to not only use devices regularly but also monitor their health status. For instance, insulin pumps have changed significantly over the last decade. These pumps help to deliver the right amount of glucose to a diabetic and stop when the threshold is reached. Sensors continually monitor a patient and indicate low blood glucose levels. Such advancements are expected to fuel the growth of the devices market for many health conditions during the forecast period. Segmentation by application and analysis of the self-care medical devices market  -Self-monitoring of blood glucose (SMBG)  -Peritoneal dialysis  -Sleep apnea  -Insulin pumps  -Body temperature monitors  -Inhalers  -Pedometers  -Blood pressure monitors  -Nebulizers  -Male external catheters  -Holter monitors During 2015, the SMBG devices segment of the self-care devices market accounted for the largest market share and is expected to generate revenues of close to USD 17 billion by the end of the forecast period. An increased incidence of diabetes in adults and children alike globally is driving the demand for more SMBG devices. Geographical segmentation and analysis of the self-care medical devices market  -Americas  -APAC  -EMEA The global self-care medical care devices market will be dominated by the Americas with a market share of close to 46%. Factors fueling market growth are health issues like diabetes, respiratory disorders, incontinence among the elderly and other chronic illnesses. Ordering these devices is very easy due to online retailing, increased consumer awareness and reimbursement for use by insurance carriers. Moreover, the sales of self-monitoring medical devices products in the US have increased due to the growing awareness about chronic diseases such as CVDs, CKD, diabetes, ERSD, and obesity, which had led many individuals to undergo regular tests and check-ups. Competitive landscape and key vendors  The self-care medical devices market is saturated with the presence of many international and regional vendors. Regional players are finding it difficult to compete with well-established vendors due to factors like price, technology and product quality. Competition is expected to intensify on the basis of product extensions, innovation and mergers. Key vendors in this market are - Other prominent vendors in this market are Animas, Arkray, B. Braun Melsungen, Baxter, BioDerm, Bionime, Bioptik Technology, Chongqing Haray International Business, Coloplast, Consort Medical, DaVita Healthcare, Dexcom, Diversified Specialty Institue Holdings, Fitbit, Garmin, Gerresheimer, Gluco-Ease, GlySens, Grove Instruments, Hollister, Huaren Pharmaceutical, IA Collaborative, Insulet, Integrity Applications, Jawbone, LabStyle Innovations, LifeWatch DigiTrack, M Pharmaceutical, Medical Components, Medisana, MicroPort, MidMark, Mortara Instrument, Nike, Nipro, Nipro Diagnostics, Nova Biomedical, NxStage Medical, NYPRO, OrSense, PARI Medical Holding, QRS Diagnostic, RPC BRAMLAGE, Scottcare, Senseonics, Sterimed, Sunrising Enterprise, Tandem, Tekcapital, Valeritas, Welch Allyn, and Wuhan HNC Technology. Key questions answered in the report include  -What will the market size and the growth rate be in 2020?  -What are the key factors driving the global self-care medical devices market?  -What are the key market trends impacting the growth of the global self-care medical devices market?  -What are the challenges to market growth?  -Who are the key vendors in the global self-care medical devices market?  -What are the market opportunities and threats faced by the vendors in the global self-care medical devices market?  -Trending factors influencing the market shares of the Americas, APAC, and EMEA.  -What are the key outcomes of the five forces analysis of the global self-care medical devices market? For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Loading Integrity Applications collaborators
Loading Integrity Applications collaborators